Trial Profile

A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Dec 2024 According to a Transposon Therapeutics media release, data from this trial will be presented at the 35th International Symposium on ALS/MND.
06 Nov 2024 Results presented in the Transposon Therapeutics Media Release.
06 Nov 2024 According to a Transposon Therapeutics media release, results from its Phase 2 study of TPN-101 will be presented at the 7th Annual ALS ONE Research Symposium on Thursday, November 14, 2024, at 2:00 pm EST.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com